原 著：《 Tumor Microenvironment》译 著：《肿瘤微环境》

This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. 

The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. 

Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.

1. Functional In Vivo Imaging of Tumors

2. New Technologies to Image Tumors 

3. Systemic Correlates of the Tumor Microenvironment 

4. Adaptive Immunity and the Tumor Microenvironment 

5. The Biology of Immune-Active Cancers and Their Regulatory Mechanisms 

6. The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier 

7. The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications 

8. The Immune Landscape in Women Cancers 

9. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors 

10. Immunogenic Cell Death Driven by Radiation—Impact on the Tumor Microenvironment 

11. CAR T Cell Therapy Progress and Challenges for Solid Tumors